Navigation Links
Varian Medical Systems Reports Results for First Quarter of Fiscal Year 2011
Date:1/26/2011

r changes in third-party reimbursement levels; currency exchange rates and tax rates; demand for the company's products; the company's ability to develop, commercialize, and deploy new products such as the TrueBeam platform; the company's ability to meet Food and Drug Administration (FDA) and other regulatory requirements for product clearances or to comply with FDA and other regulatory regulations or procedures; changes in the regulatory environment, including with respect to FDA requirements; challenges in reducing or eliminating ongoing commitments retained from our discontinued research instruments business; the effect of adverse publicity; the company's reliance on sole or limited-source suppliers; the impact of reduced or limited demand by sole purchasers of certain X-ray tubes; the company's ability to maintain or increase margins; the impact of competitive products and pricing; the potential loss of key distributors or key personnel; challenges to public tender awards and the loss of such awards or other orders; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.

A summary of earnings and other financial information follows.Varian Medical Systems, Inc. and Subsidiaries Consolidated Statements of Earnings(Unaudited)(Dollars and shares in millions, except per share amounts)Q1 QTR2011Q1 QTR2010Net orders

$

592.8$

495.6  Oncology Systems459.0436.5  X-Ray Products111.999.0  Security & Inspection Products21.322.1  Varian Particle Therapy (1)0.6(62.0)Order backlog

$

2,205.6$

2,009.1Revenues    

$

579.9$

540.9  Oncology Systems452.4430.1  X-Ray Products111.691.4 
'/>"/>

SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 1, 2015 The Coalition of State ... and regional professional rheumatology societies, today released the ... explored perceptions of biosimilars and the potential impact ... Biosimilars are medicines that are highly similar, ... notably different from generic medications in that it ...
(Date:7/1/2015)... N.J. , July 1, 2015 ContraVir ... focused on the development and commercialization of targeted antiviral ... Cantor Fitzgerald Inaugural Healthcare Conference taking place in ... 2015 at Le Parker Meridien Hotel. ... an overview of the Company,s business during his live ...
(Date:7/1/2015)... , July 1, 2015 Eli Lilly and Company ... the second quarter of 2015 on Thursday, July 23, 2015. ... with the investment community and media to further detail the ... at 9 a.m. EDT. Investors, media and the general public ... a link that will be posted on Lilly,s website at ...
Breaking Medicine Technology:Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2ContraVir to Present at Cantor Fitzgerald Inaugural Healthcare Conference 2Lilly Confirms Date and Conference Call for Second-Quarter 2015 Financial Results Announcement 2
... AUSTIN, Texas, June 27, 2011 Luminex Corporation (NASDAQ: ... its acquisition of privately-held EraGen Biosciences, Inc., an innovator ... genetic applications, for $34 million in cash. ... EraGen acquisition will add between $5 million and $7 ...
... ChemoCentryx, Inc. today announced that the Company,s novel ... in experimental models.  These data implicate CCR2-driven processes ... associated complications such as diabetic nephropathy.  Results were ... Improves Renal Function and Hyperglycemia in Preclinical Models ...
Cached Medicine Technology:Luminex Corporation Completes Acquisition of EraGen Biosciences, Inc. 2Luminex Corporation Completes Acquisition of EraGen Biosciences, Inc. 3ChemoCentryx Reports Novel CCR2 Antagonist Significantly Improves Kidney Function and Hyperglycemia in Models of Type 2 Diabetes 2ChemoCentryx Reports Novel CCR2 Antagonist Significantly Improves Kidney Function and Hyperglycemia in Models of Type 2 Diabetes 3
(Date:7/2/2015)... ... July 02, 2015 , ... Cs &A, the leader ... announced the release and publication of their newest offering to complement the existing ... Newsletter. , Designed in support of coverage for the full spectrum of ...
(Date:7/2/2015)... ... July 02, 2015 , ... Maddock Douglas is ... and business models. To help manage the increasing demand for innovation as a ... as SVP of Strategic Engagements. , Benkendorf is a seasoned management executive with ...
(Date:7/1/2015)... ... 01, 2015 , ... In the United States, summer has always been the ... Saudi Arabia and Dubai, the summer temperatures are so hot, that July vacationers often ... Sam Saleh of ORA Dentistry Spa notes that a trip to the United States, ...
(Date:7/1/2015)... ... 01, 2015 , ... Dr. Jian-Dong Li, a professor and ... Georgia Research Alliance Eminent Scholar in Inflammation and Immunity, has received a five-year, ... The grant from the National Institute on Deafness and Other Communication Disorders of ...
(Date:7/1/2015)... ... July 01, 2015 , ... The federal court ... http://www.injurybeacon.com/levaquin/lawsuit/ ) has granted the Defendants’ Motion for Summary Judgment. According to an ... June 26th, the Court rejected the Plaintiff’s assertion that one manufacturer can ...
Breaking Medicine News(10 mins):Health News:Cs &A Releases the SEMI TIMING Newsletter Specific to the Semiconductor Timing Industry 2Health News:Cs &A Releases the SEMI TIMING Newsletter Specific to the Semiconductor Timing Industry 3Health News:Cs &A Releases the SEMI TIMING Newsletter Specific to the Semiconductor Timing Industry 4Health News:Business Builder Mark Benkendorf Joins Innovation Firm Maddock Douglas 2Health News:Dr. Sam Saleh Invites Vacationing International Patients to Get a Same-Day Hollywood Smile During the July Travel Season 2Health News:Institute for Biomedical Sciences Researcher Gets $1.6 Million to Develop Anti-Inflammatory Drug 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 3
... By Jenifer Goodwin HealthDay Reporter , THURSDAY, ... Ellie, was diagnosed with a severe peanut allergy, the New ... and never leaves home without it. The device contains ... even life-threatening allergic reactions. But it,s not only Able ...
... , THURSDAY, Feb. 9 (HealthDay News) -- The number ... to engage in regular exercise has increased steadily over ... health officials. The U.S. Centers for Disease Control ... more Americans lower their risk for chronic illnesses, reduce ...
... Feb. 9, 2012 Wake Forest Baptist Medical Center ... into tumors and heating them with a quick, 30-second laser ... effort involving kidney tumors was published in 2009, but now ... tumors, specifically the tumor initiating cancer stem cells. These stem ...
... and under-studied subset of diseases affecting the lymphatic system ... disease is the focus of a special issue of ... published by Mary Ann Liebert, Inc. . The ... Guest Editor, and Journal Associate Editor Francine ...
... certain cancer cells may exhibit greater flexibility than normal ... tumor growth. Now computer simulations developed by Boston University ... the University of Texas at Austin appear to support ... cells that they,ve created indicates that the softening of ...
... 9 (HealthDay News) -- ,The longer Hispanic women live in the ... birth, a new study says. Researchers analyzed data from 2,141 ... the U.S. National Health and Nutrition Examination Survey 1999-2006. The ... for women who had lived in the United States for less ...
Cached Medicine News:Health News:More People Need Training in Lifesaving Epinephrine Use, Advocates Say 2Health News:More People Need Training in Lifesaving Epinephrine Use, Advocates Say 3Health News:More U.S. Doctors Are Urging Patients to Exercise: CDC 2Health News:Nanotube therapy takes aim at breast cancer stem cells 2Health News:Boston University research suggests new pathways for cancer progression 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: